Simplify Asset Management Inc. Purchases New Position in SAB Biotherapeutics, Inc. $SABS

Simplify Asset Management Inc. acquired a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 208,227 shares of the company’s stock, valued at approximately $779,000. Simplify Asset Management Inc. owned 0.44% of SAB Biotherapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of SABS. Jefferies Financial Group Inc. acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $2,170,000. Woodline Partners LP purchased a new position in SAB Biotherapeutics in the 3rd quarter worth approximately $5,730,000. Vivo Capital LLC acquired a new stake in SAB Biotherapeutics in the third quarter valued at approximately $22,954,000. RA Capital Management L.P. purchased a new stake in shares of SAB Biotherapeutics during the third quarter valued at approximately $8,847,000. Finally, Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics during the third quarter valued at approximately $8,847,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $3.90 on Monday. The stock has a market capitalization of $298.21 million, a PE ratio of -1.85 and a beta of 0.55. The business’s fifty day moving average price is $3.83 and its 200 day moving average price is $3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. SAB Biotherapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Equities research analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on SABS shares. Rodman & Renshaw restated a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Chardan Capital raised their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Finally, Citigroup began coverage on SAB Biotherapeutics in a research report on Friday. They set a “buy” rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.00.

SAB Biotherapeutics Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.